ERBB2 and pancreatic ductal adenocarcinoma: The targets extensively investigated in pancreatic cancer include MSLN, HER2, EGFR, CEA, and CD133, being particularly notable as a well-studied antigen in the field of immunotherapy for pancreatic ductal adenocarcinoma (PDAC).